Description

Vincristine Sulphate Injection

Healthy Inc is a specialized global supplier and exporter of high-potency antineoplastic and oncology therapies. We provide high-purity Vincristine Sulphate Injection (1 mg/ml & 2 mg/2 ml), manufactured in WHO–GMP certified sterile cytotoxic facilities. This “Vinca Alkaloid” specialist is a mandatory export to oncology centers, pediatric hospitals, and government health ministries in Africa, LATAM, and Southeast Asia, serving as a cornerstone chemotherapeutic agent for acute leukemias and malignant lymphomas.

Product Overview

This formulation contains Vincristine Sulphate, a highly potent, cell-cycle-specific antineoplastic drug originally derived from the Madagascar periwinkle plant (Catharanthus roseus).

The “Mitotic Arrest” Specialist:

• Mechanism (Microtubule Inhibition): Vincristine exerts its cytotoxic effect by binding specifically to tubulin dimers inside the cancer cell. This binding prevents the tubulin from polymerizing to form microtubules, which are essential for the formation of the mitotic spindle. Without the spindle, the cancer cell cannot divide and is permanently arrested in the metaphase of cell division, leading rapidly to apoptosis (programmed cell death).
• Pediatric & Hematologic Backbone: It is highly effective in rapidly proliferating cancers and remains a foundational component of major combination chemotherapy regimens, such as CHOP (for Non-Hodgkin’s Lymphoma) and MOPP (for Hodgkin’s Disease), as well as standard induction protocols for Acute Lymphoblastic Leukemia (ALL).
• Bone Marrow Sparing: Unlike many other chemotherapeutic agents, Vincristine generally causes very little bone marrow suppression (myelosuppression), making it an ideal candidate to combine with other myelosuppressive drugs.

Product Composition & Strength

We supply this product as a Sterile, Clear, Colorless Aqueous Solution in glass vials.

*Pack Sizes: Single Vial encased in specialized protective cytotoxic packaging.

Technical & Logistics Specifications

Critical data for Pharmaceutical Importers and Oncology Distributors.

Manufacturing Authority

Marketed and Distributed by Healthy Inc from WHO-GMP & ISO 9001:2015 certified units.

• HPAPI Isolation Technology: Vincristine is a High-Potency Active Pharmaceutical Ingredient (HPAPI). It is manufactured in completely segregated, negative-pressure cytotoxic isolator suites to ensure absolute operator safety and eliminate any risk of cross-contamination with non-oncology products.
• Overwrap & Safe Handling: Vials are routinely supplied with specialized clear shrink-wrap or plastic sleeves to prevent shattering and protect healthcare workers from accidental exposure to this highly toxic vesicant during transit and handling.

Therapeutic Indications (Human Use)

Indicated for use alone or in combination with other oncolytic drugs for:

• Acute Lymphoblastic Leukemia (ALL): Highly successful in inducing remission, particularly in pediatric patients.
• Lymphomas: Hodgkin’s disease and Non-Hodgkin’s malignant lymphomas.
• Solid Tumors: Rhabdomyosarcoma, neuroblastoma, and Wilms’ tumor.
• Idiopathic Thrombocytopenic Purpura (ITP): Used off-label in refractory cases resistant to corticosteroids and splenectomy.

Dosage & Administration

Recommended Dosage (Strictly as per Medical Oncologist):

• Route: INTRAVENOUS (IV) USE ONLY.
• Standard Adult Dose: Typically 1.4 mg/m² (body surface area) administered once a week. Maximum single dose generally should not exceed 2 mg to minimize severe neurotoxicity.
• Standard Pediatric Dose: 1.5 to 2 mg/m² administered once a week.
• Administration Technique: Administered as a slow IV push over 1 minute directly into a freely running intravenous infusion (Normal Saline or 5% Dextrose) via a central line or a newly established, secure peripheral IV.

Safety Warnings (CRITICAL):

• BLACK BOX WARNING (Fatal Intrathecal Error): FATAL IF GIVEN INTRATHECALLY. FOR INTRAVENOUS USE ONLY. Administration into the spinal fluid causes ascending paralysis, massive central nervous system destruction, and inevitable death. Syringes containing this product must be explicitly labeled with this warning.
• Vesicant Hazard (Tissue Necrosis): Vincristine is a powerful vesicant. Extravasation (leakage into surrounding tissue) during IV administration will cause severe pain, tissue sloughing, and necrosis. Stop injection immediately if burning occurs; apply local heat and inject hyaluronidase locally per institutional protocol.
• Neurotoxicity: Dose-limiting side effect. Causes peripheral neuropathy (loss of deep tendon reflexes, numbness, tingling), autonomic neuropathy (severe constipation, paralytic ileus), and cranial nerve palsies.

Global Export & Contract Manufacturing Services

Healthy Inc stands as a premier Pharmaceutical Exporter in India, dedicated to serving the needs of international Pharma Traders, Wholesalers, and Bulk Drug Distributors. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) services for Oncology and Cytotoxic Injectables, allowing brands to launch high-quality generic medicines under their own label. Whether you are looking for a reliable Hospital Tender Supplier for government procurement in Africa or a B2B Pharma Marketplace partner for Latin America, our logistics network ensures secure cold-chain delivery. We actively support Pharmaceutical Drop Shipping models and bulk indenting, ensuring that every Generic Medicine Wholesaler receives WHO-GMP certified products at competitive rates.